Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

Completed · Phase 1

Conditions studied: Geographic Atrophy

In brief

Safety Assessment of APL-2 in Patients with Geographic Atrophy

Key facts

Study ID

NCT03777332

Run by

Apellis Pharmaceuticals, Inc.

People needed

19

Starts

2018-11-05

Expected to finish

2021-04-01

Last updated by the study team

2021-11-10

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• California Retina Consultants — Bakersfield, California, United States
• Retina Vitreous Associates Medical Group — Beverly Hills, California, United States
• The Retina Partners — Encino, California, United States
• Ophthalmic Consultants of Boston — Boston, Massachusetts, United States
• Retina Consultants of Houston — The Woodlands, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.